
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what's possible.
We are seeking a Sr. Specialist, Quality Assurance Operations (QA Ops) for a temporary assignment. The Sr. Specialist will provide quality expertise to support QA Operations in the development and commercialization of Kyverna’s products, ensuring compliance with applicable US, EU, and ICH regulatory requirements. The Sr. Specialist will contribute to the execution and continuous improvement of QA Operations as the organization continues to grow and evolve. This role requires strong collaboration with cross-functional teams, particularly in supporting batch record review and disposition activities.
Title: Senior. Specialist, Quality Assurance Operations (Contract)
Reports to: Sr Director, Quality Assurance Operations
Location: Remote or Hybrid (Emeryville, CA)
Duration: 6+ Months
Hourly Rate: $55–$65/hour (National)

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.